Dark

Check out our Level2View

CPSR
Calamos S&P 500 Structured Alt Protection ETF - March
stock NYSE ETF

At Close

May 5, 2025 2:42:15 PM EDT

23.78USD+0.084%(+23.78)202

0.00Bid 0.00Ask 0.00Spread

Pre-market

Dec 31, 1969 7:00:00 PM EST

0.00USD0.000%(0.00)0

After-hours

Dec 31, 1969 7:00:00 PM EST

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 14, 2022

05:37AM EST Gelesis, Maker Of Weight Loss Pill, Concludes SPAC Deal; Trading Kickstarts Today Benzinga

Jan 13, 2022

06:41PM EST Gelesis(r), the Maker of Plenity(r) for Weight Management, Will Debut as a Publicly Traded Company Following the Closing of Its Business Combination with Capstar Business Wire

Jan 11, 2022

10:38AM EST 52 Weeks High And Low Article Benzinga

Jan 10, 2022

10:03AM EST Texas-based finserv company, Capstar Special Purpose Acquisition Corp. (CPSR), is trading 21% higher on Monday despite the company not reporting any stock-specific news to boost the stock. The company is trading at the highest since getting listed. RTTNews

Jan 5, 2022

07:00AM EST Gelesis Adds Inogen Co-Founder and Former CFO Ali Bauerlein to Board of Directors and Audit Committee Business Wire

Dec 1, 2021

07:00AM EST Gelesis' FDA-Cleared Weight Management Approach, Plenity(r), Now Broadly Available and Leading Nutrition Authority Joy Bauer, MS, RDN, CDN, Joins as Chief Nutrition Officer Business Wire

Nov 18, 2021

07:37AM EST PureTech Founded Entity Gelesis Receives $30M Plenity Order From Ro Benzinga

07:11AM EST Gelesis Receives $30 Mln Plenity Order From Ro RTTNews

07:00AM EST Gelesis Receives $30 Million Plenity Order from Ro Business Wire

Nov 10, 2021

08:35AM EST Capstar Special Purpose Acquisition Corp. Reports Terms Of Deal With Gelesis Revised To Imply Equity Value Of $675M, Down From $900M Benzinga

Nov 1, 2021

06:19AM EDT Capstar Special Purpose Acquisition Merging Partner Gelesis Announces Nature's Scientific Reports Features Gelesis' Novel and Foundational Biomimetic Platform for Treating Obesity and Conditions Related to Diet-Induced Gut Damage Benzinga

06:08AM EDT Nature's Scientific Reports Features Gelesis' Novel and Foundational Biomimetic Platform for Treating Obesity and Conditions Related to Diet-Induced Gut Damage Business Wire

Oct 28, 2021

07:00AM EDT Two Senior Scientific Leaders at Gelesis Awarded Top Industry Honors Business Wire

Aug 4, 2021

10:35AM EDT FDA-Approved Weight Loss Drug Plenity's Parent Announces SPAC Deal: What Investors Should Know Benzinga

Jul 19, 2021

07:03AM EDT Gelesis To Go Public Through Merger With Capstar Special Purpose Acquisition Corp.; Pro Forma Implied Market Value Of Approximately $1.3B And Enterprise Value Of Approximately $1.0B Benzinga

Jun 2, 2021

04:30PM EDT Capstar Special Purpose Acquisition Corp. Receives Expected Notice from NYSE Regarding Delayed Quarterly Report Business Wire

Share